New Vaccines for Prostate Cancer A/Prof Kristen Radford Cancer Immunotherapies Group, Mater Research School of Biomedical Sciences, University of Queensland Translational Research Institute, Brisbane Australia kristen.radford@mater.uq.edu.au
Teaching the immune system to fight cancer 1. Turning off the breaks Immune checkpoint inhibitors eg Ipilimumab (Yervoy, anti-CTLA-4) Tremelimumab (anti-CTLA-4) MEDI4736 (anti-PD-L1) 2. Transferring cancer-specific killer T cells Adoptive T cell therapies 3. Cancer vaccines Dendritic cell therapies eg Sipuleucil-T – Provenge, Dendreon
Dendritic cells are master regulators of immune responses 1. Initiate immune responses against pathogens and cancers 2. Maintain tolerance and homeostasis
Dendritic cell immunotherapy for cancer • >200 published clinical trials • Safe, low toxicity • Induction of anti-tumour immunity, some clinical benefit
Identification of the “cancer fighting” DC in humans Journal of Experimental Medicine, 2010
Immunotherapy targeting the “cancer fighting” DC Antibody specific for lymph node “cancer fighting” DC cancer killer target(s) T cells vaccination tumour cells Advantages • Cancer targets directly reach the “cancer fighting” DC • Practical and cost effective manufacture • Applicable to a wider range of patients
Recommend
More recommend
